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Subjective memory complaints (SMCs) are common in older adults that can often predict further cognitive impairment. No proven
effective agents are available for SMCs. The effect of BrainPower Advanced, a dietary supplement consisting of herbal extracts,
nutrients, and vitamins, was evaluated in 98 volunteerswith SMCs, averaging 67 years of age (47–88), in a randomized, double-blind,
placebo-controlled trial. Subjective hypomnesis/memory loss (SML) and attention/concentration deficits (SAD) were evaluated
before and after 12-week supplementation of BrainPower Advanced capsules (𝑛 = 47) or placebo (𝑛 = 51), using a 5-point memory
questionnaire (1 = no/slight, 5 = severe). Objective memory function was evaluated using 3 subtests of visual/audio memory,
abstraction, and memory recall that gave a combined total score. The BrainPower Advanced group had more cases of severe SML
(severity ⩾ 3) (44/47) and severe SAD (43/47) than the placebo group (39/51 and 37/51, < 0.05, < 0.05, resp.) before the treatment.
BrainPower Advanced intervention, however, improved a greater proportion of the severe SML (29.5%)(13/44) (𝑃 < 0.01) and SAD
(34.9%)(15/43)(𝑃 < 0.01) than placebo (5.1% (2/39) and 13.5% (5/37), resp.).Thus, 3-month BrainPower Advanced supplementation
appears to be beneficial to older adults with SMCs.
1. Introduction
Memory is the ability of an individual to record, retain, and
recall sensory stimuli, events, and information over short
and long periods of time. Deficits in memory function can
compromise one’s quality of life and ability to work.
Hypomnesis/forgetfulness/memory decline can occurwith
aging or as results of subhealth conditions [1]. Complaints
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about memory impairment, or subjective memory com-
plaints (SMCs), are common in elderly people but are rarely
detected by clinicians using objective memory function tests
due to the subtle and heterogeneous nature of SMC [2–5].
SMCs are a criterion of mild cognitive impairment (MCI),
which is common in older adults and in people who have
experienced subhealth conditions [6–12].
MCI is an intermediary status between normal aging and
prodromal memory decline [6, 13]. Individuals with MCI
appear to have intact general cognitive function and activities
of daily living, but their memory is impaired for normal age.
The prevalence ofMCI is estimated at 3%–19% in adults older
than 65 years and 15% in adults older than 75 years [14–18].
Less than half of people withMCI are stable or able to reverse
back to normal memory function again within 5 years [19–
21].
SMC and MCI are often associated with a decline in
episodic memory (a recollection of specific past events) [22–
24], which ismost frequently found in those with the amnesic
subtype MCI [22–28]. Positron emission tomography (PET)
brain image studies show that people with SMC are charac-
terized with elevated brain beta-amyloid [25–27]. Increased
amyloid deposition has an early and subclinical impact on
cognition that precedes hypometabolism [28] and impairs
blood vessel functions [29] that could contribute to increased
inflammation in amnestic mild cognitive impairment [30].
Latent insufficiency of cerebrovascular circulation and
loss of phospholipid asymmetry may underlie early mani-
festation of SMC and MCI [31] and could be a risk factor
for episodic nonspecific complaints of mild cognitive deficit,
regional hypoperfusion, and hypometabolism [32–38].
Episodic memory processes depend on the integrity
of the medial temporal lobe, hippocampus, the posterior
parietal cortex, and lateral prefrontal cortex (PFC) [33–35].
Imaging studies have shown an asymmetric hemispheric
encoding/retrieval (HERA) pattern in young adults where
the left PFC and temporo-occipital cortex are involved in
encoding and the right PFC is involved in retrieval of
the stored information [36–39]. During normal aging, PFC
activation becomes less asymmetric during memory tasks.
Normal or high-performing older adults balance age-related
neural decline through neuroplasticity, which reorganizes
neurocognitive networks. The subnormal or low-performing
older adults use a network similar to young adults, but
inefficiently [36, 40].
Abnormal cholinergic and glutamatergic neurotransmis-
sions are thought to be involved in SMC and MCI [41–
43]. Cognitive decline in older adults is associated with
a loss of cholinergic function (cholinergic hypofunction)
including a reduction in choline acetyltransferase (ChAT),
muscarinic and nicotinic acetylcholine receptor binding sites,
and concentrations of acetylcholine in the synaptic clefts
[43, 44]. Glutamatergic overstimulation (excitotoxicity) of
the postsynaptic NMDA receptors could also lead tomemory
impairment [45].
Currently, there are no effective and safe pharmaceutical
drugs for SMC and MCI. Prevention of the progression of
the symptomatic development could be the best strategy
[46]. Although acetylcholinesterase inhibitors (AChEIs) and
N-methyl D-aspartate (NMDA) receptor antagonists have
been used for treatment of people with varying degree of
memory deficits, their effects on cognition and memory
improvement are often negative [47–54]. A portion of people
with MCI, however, may respond favorably to AChEIs (15%–
35%) and NMDA receptor antagonists (30%) [55–57], but
usually after high doses or long treatment, and with potential
adverse effects, such as nausea, vomiting, diarrhea, headache,
hypertension, and hepatotoxicity [58–64].
A variety of plant-derived compounds have been studied
as potential enhancers of memory and cognitive function
[65] with potential mechanisms on (1) modulation of neu-
ronal membrane integrity; (2) modulation of the cholinergic
system through inhibition of acetylcholinesterase (AChE)
or stimulation of muscarinic and nicotinic receptors; (3)
neuroprotection against NMDA receptor excitotoxicity; (4)
anti-inflammatory and antioxidant activities; (5) improved
cerebral blood flow and microperfusion.
Table 1 lists some herbal extracts and compounds that are
active ingredients of BrainPower Advanced, the formulation
used in this pilot study. BrainPower Advanced is a dietary
supplement formulated to support healthy memory and
cognitive function in adults. Its key ingredients include
extracts ofGinkgo biloba (flavonoids, terpenoids, and terpene
lactones), Camellia sinensis leaf (tea polyphenols), Catharan-
thus roseus (vinpocetine), kola nut (Cola nitida, caffeine),
Huperzia serrata (hupA and hupB), phosphatidylserine (PS),
L-tyrosine, L-pyroglutamic acid, acetyl-L-carnitine, choline
bitartrate, L-glutamine, L-phenylalanine, L-cysteine, vitamin
B6, and vitamin B12 (Table 1).
PS is a key integrative phospholipid component of
neuronal cell membranes and represents 15% of the total
phospholipid pool. PS acts to maintain membrane integrity
and neuroplasticity, buffer oxidative stress, facilitate neuro-
transmitter release, and increase brain glucose metabolism
[66–69]. Phospholipid deficits in neuronal membranes
are involved in age-related brain-structural and cognitive
decline. A decline of PS and other phospholipids in neuronal
membranes has been associated with memory impairment
and cognitive deficits whereas dietary PS and phospholipid
supplements have prevented or reversed such deficits [70–
75]. PS supplementation improved learning capacity and
memory in rodents [76, 77] and improved physical and
mental performance such as long-term memory and recog-
nition in elderly people with cognitive decline [73, 78–80],
in stressed young adults [81], and in children with attention
deficit hyperactivity disorder [82].
Vinpocetine (ethyl apovincaminate) is synthesized from
the alkaloid vincamine, an extract from the leaf of the
lesser periwinkle plant (Catharanthus roseus). Vinpocetine
has been used widely in Japan and Europe for the treatment
of cognitive decline since the late 1970s. Vinpocetine can
improve cerebral blood flow and glucose metabolism in the
thalamus and basal ganglia and the occipital, parietal, and
temporal cortex [83–86]. Previous studies have confirmed
that vinpocetine can inhibit beta-amyloid-induced activa-
tion of NF-𝜅B, inflammation, and cytokine production and
interferes with many stages of the ischemic cascade: ATP
depletion, activation of voltage-sensitive Na(+) and Ca(++)
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channels, and glutamate and free-radical release (antioxi-
dant activity) [87–91]. Vinpocetine treatment for 18 months
significantly improved cognitive functions, overall health
status, and quality of life in people with chronic cerebral
hypoperfusion [92]. Vinpocetine is considered prophylactic
for MCI [92–94].
Huperzine A (hup A), is a quinolizidine-related alkaloid
isolated from Huperzia serrata (Thunb.) Trevis. Hup A is
a competitive, reversible, and well-tolerated inhibitor of
AChE that is more potent than current memory-promoting
agents (donepezil, rivastigmine, and galantamine) [95–98].
Hup A is also a competitive NMDA receptor inhibitor and
an antagonist of A𝛽-induced neurotoxicity [99–108]. It has
significant antioxidative, antiapoptotic, and neuroprotective
effects [100].HupAhas beenused for enhancingmemory and
mental function in healthy people [101] and in animal models
of cognitive deficits [97] without showing any obvious serious
adverse effects [102]. Other studies suggest, however, that hup
A has limited effects on cognition. One recent multicenter,
randomized, placebo-controlled trial showed that a dose of
0.4mg daily, but not 0.2mg daily, of hup A was effective
in improving cognition in people with moderate cognition
decline [103].
The active components of the leaf extract of Ginkgo
biloba (EGb) consist of flavonoids, terpenoids, and terpene
lactones (ginkgolides and bilobalide). EGb has long been
used in traditional Chinese medicine [104, 105]. EGb has
also been prescribed for memory and concentration com-
plaints in Germany and France since the 1960s [106, 107].
EGb protects neuronal cell membranes and mitochondria
from free-radical damage [108]; reduces the aggregation and
toxicity of beta-amyloid [109, 110]; promotes hippocampal
neurogenesis [111–116]; decreases blood viscosity [117, 118];
enhances microperfusion [119]; improves neurotransmission
of glutamatergic [120–122], dopaminergic, and cholinergic
systems [123, 124]; and improves learning and memory in
animal models [125–129].
Recent meta-analyses of multiple randomized, controlled
trials suggest that EGb may be effective for reversing or
delaying age-related memory deficits [130–135]. However,
two recent large-scale studies, conducted in more than 6000
participants aged 70 years and over [136, 137], failed to
confirm such effects. One explanation is that, due to the
particularly long incubation phase of severe memory decline
(20–30 years), a quick reduction in the incidence of severe
memory deficits by EGb is unrealistic, or EGb is only effective
in subjects at early stages of memory decline such as SMC
and/orMCI, but not in advanced stage ofmemory deficits. To
support this, short-term and acute EGb administration could
be used to enhance specific memory and cognitive functions
in cognitively intact older, middle-aged, and younger healthy
volunteers [138]. In addition, coadministration of EGb andPS
improved secondary memory and the speed of memory task
performance [125, 126].
Other studies show that deficits or dysregulation in brain
metabolism is linked with aging-related cognition decline
and that decline could be reversed through nutrients and
vitamin supplements such as acetyl-L-carnitine, vitamin B6,
and vitamin B12 [139–151]. L-Tyrosine is a precursor to
L-dopa and catecholamines, an imbalance of which may be
involved in cognitive dysfunction [127, 128].
The preventive effects of coffee, tea, and caffeine con-
sumption on late-life cognitive decline and dementia have
been extensively reviewed recently [129]. Besides the well-
known short-term enhancing effects, some studies examined
the long-term effects and showed that coffee, tea, and caffeine
consumption could protect against late-life cognitive impair-
ment/decline and dementia.These findings, however, are still
considered preliminary [129].
Green tea (Camellia sinensis) extract enhances pari-
etofrontal connectivity during working memory processing
[152] and protects against okadaic acid-induced acute learn-
ing and memory impairments in rats [153]. A recent review
suggests that the green tea constituent theanine could have
therapeutic effects against psychiatric and neurodegenerative
disorders includingmild cognitive impairment and dementia
through multiple mechanisms such as inhibition of NMDA-
induced neurotoxicity, enhanced brain GABA and glycine
content, and enhanced BDNF-related neuroprotection [154].
Most of these mechanistic studies, however, were done on
animals.
Coadministration of multiple medicinal herbal ingredi-
ents is a common practice in traditional Chinese medicine.
The main goal of such practices is to potentiate the bioavail-
ability, activity, and efficacy of the key therapeutic ingredients
and to minimize or antagonize potential toxicities associated
with the ingredients.
The objective of this exploratory, randomized, placebo-
controlled trial was to evaluate the safety and effectiveness of
short-term administration of BrainPower Advanced, a multi-
ingredient dietary supplement, on SMCs in older adults.
2. Methods
2.1. Samples and Participants Recruitment. This study was
conducted between December 15, 2011, and April 10, 2012, at
the Si Tang Community Health Service Center in Baoshan
district in Shanghai, China. Community volunteers of older
adults were recruited by self-referral in response to media
coverage and word of mouth. All study procedures were
conducted in accordance with the Helsinki Declaration of
1975 and were approved by the Shanghai Jiao Tong University
Medical Center Institutional Review Board. Informed con-
sent was obtained from all participants prior to enrollment
into the study.
Subjects who met the following criteria were eligible for
the study: inclusion criteria: (1) healthy males or females at
least 50 years of age; (2) having self-reported hypomnesis, for-
getfulness,memory loss, or impaired attention/concentration
as determined by a standard medical examination ques-
tionnaire; exclusion criteria: (1) having been diagnosed with
neurological diseases such as Alzheimer’s Disease, Parkin-
son’s Disease, migraine, and epilepsy; (2) having taken
any medication likely to affect brain and nervous system
function such as L-dopa, MAO inhibitors, modafinil, and
amphetamine, within 30 days before the start of the trial;
(3) having a history of severe cerebral-cardiovascular events
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(myocardial infarction, cerebrovascular disorder, acute coro-
nary syndrome, or other cerebrovascular diseases); (4) other
severe medical conditions (severe diseases of the liver,
kidneys, or lungs; malignant tumors; motor impairment;
dysphonia; visual impairment; etc.).
2.2. Randomization and Blindness. Participants were ran-
domly assigned to the BrainPower Advanced treatment
group or placebo treatment group. The randomization was
performed using a predetermined randomization codewhich
was generated by a random number generator. The numbers
generated were placed in sealed envelopes and a serial
number was assigned to each envelope according to the
sequence of allocation of the randomized number. Each
envelope was then opened sequentially according to the
admission sequence of subjects.
Trial participants and community doctors were both
blinded from the treatment (double-blind trial). Of the 101
enrolled participants, 98 participants completed the 12-week
follow-up, including 47 subjects in the BrainPower Advanced
group and 51 subjects in the placebo group. Three subjects
withdrew from the study (2 due to symptoms of diarrhea and
1 due to family objection).
The participants received similar-looking capsules in
color-coded bottles (white bottles for BrainPower Advanced
and yellow bottles for placebo). Neither the subjects nor the
medical doctors, including the study principal investigator
(Rong Shi), knew the specific color code until the end
of the study. Both the BrainPower Advanced capsules and
the placebo (which was mainly composed of flour) were
manufactured and supplied by Robinson Pharma, Inc. (Costa
Mesa, California, USA).
Each participant was instructed to take 2 capsules
with meals daily for 12 weeks and a new batch of sup-
plements was dispensed every 4 weeks during follow-up
sessions. Changes in subjective hypomnesis/memory loss
and attention/concentration deficits were recorded using a
self-administrated medical questionnaire. Memory function
capacity was evaluated using a subset of tester-administered
memory tests before and after the 12-week intervention. All
participants were followed up each month in order to check
compliance and adverse effects.
2.3. Evaluation of Subjective Memory Complaints. Two
aspects of subjective memory complaints, that is, subjective
hypomnesis/forgetfulness/memory loss (SML) and subjec-
tive attention/concentration deficits (SAD), were screened
using a self-administered 5-point scale (1 = no symptoms
or occasional slight symptoms complaints; 2 = slight/mild
symptom complaints; 3 = moderate severe symptom com-
plaints; 4 = severe symptom complaints; 5 = very severe
symptom complaints) included in a medical questionnaire
that included the demographics andmedication history of the
participants. Because relatively fewparticipants scored 1 and 2
points in thememory questionnaire, participants who scored
1 and 2 points were combined as the “slight symptom” group,
and participants who scored 3, 4, and 5 points were combined
as the “severe symptom” group for further statistical analysis.
2.4. Evaluation of Objective Memory Function. The short-
term working memory of the participants was evaluated
using three simple tester-administered subtests constructed
and validated for the Chinese population [155].
(1) Visual/Auditory Memory (1 Point for Each Correct Answer,
a Maximal Total of 5 Points). Subjects were allowed to watch
5 film clips in 5 minutes (1 minute per film clip). The films
were selected from a pool of popular old Chinese films that
all participants should have been familiar with. The subjects
were then asked to recall the correct order and content of the
films based on the movie listings provided by the tester.
(2) Abstracting (1 Point for Each Correct Answer, a Max-
imal Total of 5 Points). Subjects were shown 5 different
pictures/images of cartoon characters (such as a policeman,
soldier, medical doctor, nurse, taxi driver, bus driver, school
teacher, university professor, cook, waitress, and tour guide)
on a computer screen and were asked to recall them immedi-
ately.
(3) Memory Recall (1 Point for Each Correct Answer, a
Maximal Total of 5 Points). Subjects were shown 5 consecutive
pictures of famous historical landscapes located in different
Chinese cities and were asked to recall the pictures’ contents
and their locations.
2.5. Statistics Analysis. EpiData 3.02 software was used for
the establishment of the database. SPSS 20.0 software was
used for statistical analysis. Group data were presented as the
mean ± s.d. Mean differences of the variables between the
BrainPower Advanced and placebo groups were compared
using Student’s 𝑡-test for variables with normal distribution
or using nonparametric tests for variables with nonnormal
distributions. Ridit scoring test, which is a nonparameter test
for comparing two or more sets of ordered qualitative data,
was used for evaluating the changes in the symptom severity
score of SML and SAD in response to the intervention. The
alpha level of 𝑃 > 0.05 was chosen as being statistically
significant. All 𝑃 values reported were 2-sided.
3. Results
3.1. Participants’ Characteristics. The baseline characteristics
of age and gender and histories of alcohol intake, disease,
and medication of the participants are shown in Table 2.
There were 14 males (29.8%) and 33 females (70.2%) in the
BrainPower Advanced group and 17 males (33.3%) and 34
females (66.7%) in the placebo group.Thegender distribution
between the two groups was not significantly different (𝜒2 =
0.142, 𝑃 > 0.05), with females accounting for more than two-
thirds of the total participants. The overall average age of all
participants was 67.1 ± 10.5, with no significant difference
found between the BrainPower Advanced group (69.1 ± 9.5
years) and the placebo group (65.2 ± 11.1 years) (𝑡 = 1.839,
𝑃 > 0.05). The BrainPower Advanced and placebo groups
also showed similar patterns of alcohol intake history (𝜒2
= 0.542, 𝑃 > 0.05). However, a greater proportion of the
participants in the BrainPower Advanced group had disease
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Table 2: Demographics and medical history of the participants (𝑁 = 98).
Treatment Male Female Subtotal
Gender,𝑁 (% of subtotal)
BrainPower 14 (29.8%) 33 (70.2%) 47 (100%)
Placebo 17 (33.3%) 34 (66.7%) 51 (100%)
Combined 31 (31.6%) 69 (68.4) 98 (100%)
Age, year (mean ± s.d.)
BrainPower 69.68 ± 9.52 68.80 ± 9.60
Placebo 64.03 ±10.73 65.81 ± 11.41
Combined 69.07 ± 9.48 65.22 ± 11.1 67.07 ± 10.49
Age, year (range)
BrainPower 52.87–82.80 53.18–84.86
Placebo 47.28–83.47 49.03–88.43
Combined 52.87–84.46 47.28–88.43 47.28–88.43
History of chronic disease, yes/total (%)
BrainPower 39/47 (83.0%)
Placebo 31/51 (60.8%)
Combined 70/98 (71.4%)
History of alcohol use, yes/total (%)
BrainPower 5/47 (10.6%)
Placebo 8/51 (15.7%)
Combined 13/98 (13.3%)
History of medication, yes/total (%)
BrainPower 35/47 (74.5%)
Placebo 23/51 (45.1%)
Combined 58/98 (59.2%)
Table 3: Mean values of symptom severity of subjective hypomnesis/memory loss (SML) and subjective attention deficit (SAD) (mean ± s.d.)
before and after 12 weeks of BrainPower Advanced and placebo intervention.
Self-reported deficits Intervention Before intervention After intervention Relative to baseline (= 1)
Subjective hypomnesis/memory loss (SML) BrainPower 3.77 ± 0.89 2.94 ± 0.94 0.779840849
Placebo 3.43 ± 1.19 2.88 ± 0.77 0.839650146
Subjective concentration/attention deficit (SAD) BrainPower 3.62 ± 0.99 2.68 ± 0.89 0.740331492
Placebo 3.25 ± 1.35 2.92 ± 0.94 0.898461538
history (39/47, 83%) and medication history (35/47, 74.5%)
compared to the placebo group (31/51, 60.8%, 𝜒2 = 5.904,
𝑃 < 0.05 and 23/51, 45.1%, 𝜒2 = 8.734, 𝑃 < 0.01, resp.).
3.2. Subjective Memory Complaints (SMC). The mean value,
distribution pattern, and the differences between the Brain-
Power Advanced group and placebo group in the severity
level of subjective hypomnesis/forgetfulness/memory loss
(SML) and subjective attention/concentration deficit (SAD)
before and after the 12-week intervention are shown in Tables
3, 4(a), and 5(a).
The baseline symptom severities of SML and SAD in
the BrainPower Advanced group (3.77 ± 0.89; 3.62 ± 0.99,
resp.) were about 10% greater than those of the placebo group
(3.43 ± 1.19; 3.25 ± 1.35, resp.) (Table 3). These differences in
SML and SAD between the two groups disappeared after the
12-week intervention, primarily due to a greater proportion of
the BrainPower Advanced group showing greater reduction
of symptom severity than the placebo group (Tables 4(b) and
5(b)). The placebo group had more participants that showed
worsened symptom severity than the BrainPower Advanced
group.
Ridit scoring test shows a significant and differential
reduction in the SML (mean ± s.d. = 0.418 ± 0.236 versus
0.575 ± 0.299, 𝑃 < 0.01) and SAD symptom severity (means
= 0.424 ± 0.229 versus 0.612 ± 0.283, 𝑃 < 0.01) after
BrainPower Advanced and placebo treatment. Table 4(b)
shows that a total of 34 people reported reduced SML
symptom severity after BrainPowerAdvanced intervention (2
people by 3 points, 12 people by 2 points, and 20 people by 1
point), 12 people reported no change, and 1 person reported
worsened symptom severity (by 1 point). In comparison,
only 23 people reported reduced SML severity after placebo
intervention (1 person by 3 points, 10 people by 2 points,
and 12 people by 1 point), 15 people reported no change in
symptom severity, and 13 people reportedworsened symptom
severity (10 people by 1 point, 2 people by 2 points, and 1
person by 3 points).
Similarly, Table 5(b) shows that a total of 36 people
reported different reductions in SAD symptom severity after
BrainPower Advanced intervention (2 people by 3 points,
14 people by 2 points, and 20 people by 1 point), 9 peo-
ple reported no change, and 2 people reported worsened
symptom severity (by 1 point) (Table 5(b)). After placebo
intervention, 20 people reported different reductions in SAD
symptom severity (2 people by 3 points, 8 people by 2 points,
and 10 people by 1 point), 15 people reported no change, and
16 people reported worsened symptoms (11 people by 1 point,
3 people by 2 points, and 2 people by 3 points).
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Table 4: (a) Distribution of symptom severity levels (5-point scale) of subjective hypomnesis/memory loss (SML) in older adults before and
after BrainPower Advanced or placebo interventions. (b) Ridit scoring test of the ranked data showed that more subjects showed reduced
(−) SML symptoms and far fewer subjects showed worsened SML symptoms (+) after BrainPower Advanced intervention than after placebo
intervention,𝑃 < 0.01. (c)McNemar’s test of the combined data (2 scales: 1-2 and 3–5) of subjectivememory loss (SML) shows that BrainPower
Advanced intervention, but not placebo intervention, significantly reversed the proportion of severe SML in the older adults. It was noted,
however, that BrainPowerAdvanced group hadmore severe cases and fewermild cases of SML than the placebo group before the intervention.
(a)
Distribution of SML symptom severity
Group 1, none or slight 2, mild 3, moderate 4, severe 5, very severe
Before intervention
BrainPower group 0 (0%) 3 (6.4%) 16 (34.0%) 17 (36.2%) 11 (23.4%)
Placebo group 5 (9.8%) 7 (13.7%) 7 (13.7%) 25 (49.0%) 7 (13.7%)
Total 5 (5.1%) 10 (10.2%) 23 (23.5%) 42 (42.9%) 18 (18.4%)
After intervention
BrainPower group 2 (4.3%) 14 (29.8%) 18 (38.3%) 11 (23.4%) 2 (4.3%)
Placebo group 2 (3.9%) 12 (23.5%) 27 (52.9%) 10 (19.6%) 0 (0%)
Total 4 (4.1%) 26 (26.5%) 45 (45.9%) 21 (21.4%) 2 (2.0%)
(b)
Symptom score change BrainPower group Placebo group Total
𝑁 % 𝑁 % 𝑁 %
−3 2 4.3 1 2.0 3 3.1
−2 12 25.5 10 19.6 22 22.4
−1 20 42.6 12 23.5 32 32.7
0 12 25.5 15 29.4 27 27.6
+1 1 2.1 10 19.6 11 11.2
+2 0 0.0 2 3.9 2 2.0
+3 0 0.0 1 2.0 1 1.0
Total 47 100.0 51.0 100.0 98 100.0
(c)
Treatment group Before intervention After intervention 𝑃 value of McNemar’s test
No or slight Severe No or slight Severe
BrainPower group 3 (6.4%) 44 (93.6%) 16 (34.0%) 31 (66.0%) 0.001
Placebo group 12 (23.5%) 39 (76.5%) 14 (27.5%) 37 (72.5%) 0.791
Pearson 𝜒2 5.547 0.5
𝑃 0.019 0.479
Because the symptom severity scores are nominal vari-
ables and because only few participants of the BrainPower
Advanced group scored 1 and 2 points (Tables 4(a) and 5(a))
of SML and SAD, participants with the severity scores of 1
and 2 were combined as the “slight symptom” group and
participants with the severity scores of 3, 4, and 5 were
combined as the “severe symptom” group for further chi-
square test (Tables 4(c) and 5(c)).
It was noted that a greater proportion of the BrainPower
Advanced group (44/47, 93.6%) than the placebo group
(39/51, 76.5%) had severe SML symptoms (severity scores
⩾ 3), or a smaller proportion of the BrainPower Advanced
group had slight SML symptoms (severity scores ⩽ 2) (3/47,
6.4%) than the placebo group (12/51, 23.5%) (Pearson 𝜒2 =
5.547, 𝑃 = 0.019) before the start of the intervention (Tables
4(a) and 4(c)). Similar pretreatment differences in severe
SAD distribution existed between the BrainPower Advanced
(43/47, 91.5%) and placebo groups (37/51, 72.5%) (severity
scores ⩾ 3) (Pearson 𝜒2 = 5.852, 𝑃 = 0.016) (Tables 5(a) and
5(c)).
After the intervention, however, the BrainPower
Advanced group had fewer cases of severe SML (31) and
SAD (28) than the placebo group (37 for SML and 32 for
SAD, resp.) and the difference in SML and SAD between
the BrainPower Advanced and placebo groups was no
longer significant (Pearson 𝜒2 = 0.5, 𝑃 = 0.479; 𝜒2 = 0.104,
𝑃 = 0.748, resp.) (Tables 4(c) and 5(c)).
Placebo group analysis of the combined data showed
that the proportion of people with severe SML showed little
change after placebo intervention (reduced by 2 people, from
39 to 37, 𝑃 > 0.05) whereas the proportion of people
with severe SML dropped significantly after BrainPower
Advanced intervention (reduced by 13 people, from 44 to 31,
𝑃 < 0.001) (Table 4(c)). Similarly, the proportion of severe
SAD did not change significantly after placebo intervention
(reduced by 5 people, from 37 to 32, 𝑃 > 0.05) whereas
8 Evidence-Based Complementary and Alternative Medicine
Table 5: (a) Distribution of subjective attention deficit (SAD) symptom severity (using a 5-point questionnaire) in older adults before and
after BrainPower Advanced or placebo intervention. (b) Ridit scoring test of the ranked data showed that more people in the BrainPower
Advanced group showed reduced SAD (−) and fewer people in the BrainPower Advanced group showed no change or worsened SAD than
people in the placebo group after the interventions (𝑃 < 0.01). (c)McNemar’s test of the combined data (2 scales) of subjective attention deficit
(SAD) shows that BrainPower Advanced intervention, but not placebo intervention, reversed a significantly greater proportion of severe SAD
in the older adults. It was noted, however, that BrainPower Advanced group had more severe cases and fewer mild cases of SAD than the
placebo group before the intervention.
(a)
Distribution of SAD symptom severity
Group 1, none or slight 2, mild 3, moderate 4, severe 5, very severe
Before intervention
BrainPower group 1 (2.1%) 3 (6.4%) 16 (34.0%) 19 (40.4%) 8 (17.0%)
Placebo group 7 (13.7%) 7 (13.7%) 8 (15.7%) 22 (43.1%) 7 (13.7%)
Total 8 (8.2%) 10 (10.2%) 24 (24.5%) 41 (41.8%) 15 (15.3%)
After intervention
BrainPower group 4 (8.5%) 15 (31.9%) 21 (44.7%) 6 (12.8%) 1 (2.1%)
Placebo group 2 (3.9%) 17 (33.3%) 16 (31.4%) 15 (29.4%) 1 (2.0%)
Total 6 (6.1%) 32 (32.7%) 37 (37.8%) 21 (21.4%) 2 (2.0%)
(b)
Symptom score change BrainPower group Placebo group Total
𝑁 % 𝑁 % 𝑁 %
−3 2 4.3 2 3.9 4 4.1
−2 14 29.8 8 15.7 22 22.4
−1 20 42.6 10 19.6 30 30.6
0 9 19.1 15 29.4 14 14.3
+1 2 4.3 11 21.6 13 13.3
+2 0 0.0 3 5.9 3 3.1
+3 0 0.0 2 3.9 2 2.0
Total 47 100.0 51 100.0 98 100.0
(c)
Treatment group Before intervention After intervention 𝑃 value of McNemar’s test
No or slight Severe No or slight Severe
BrainPower group 4 (8.5%) 43 (91.5%) 19 (40.4%) 28 (59.6%) 0.001
Placebo group 14 (27.5%) 37 (72.5%) 19 (37.3%) 32 (62.7%) 0.302
Pearson 𝜒2 5.852 0.104
𝑃 0.016 0.748
the proportion of severe SAD decreased significantly after
BrainPower Advanced intervention (reduced by 15 people,
from 43 to 28, 𝑃 < 0.001) (Table 5(c)).
3.3. Memory Function Test Scores. Thememory function test
focused on 3 subareas: visual/auditory impression memory,
abstract thinking, and immediate memory recall.The subtest
scores and the combined total test scores are shown in Tables
6(a) and 6(b), respectively. The BrainPower Advanced group
had about 10% lower baseline scores than placebo group in
audio/visual memory (2.28±1.06 versus 2.51±0.81), abstract
thinking (2.40 ± 1.08 versus 2.73 ± 1.08), and combined
total memory function scores (6.85 ± 2.46 versus 7.37 ±
2.32), but similar scores in memory retrieval (2.17 ± 1.15
versus 2.18 ± 1.14). These baseline differences disappeared
after the 12-week intervention (3.43 ± 0.83 versus 3.41 ±
1.00, 3.45 ± 0.75 versus 3.47 ± 0.92, 9.66 ± 1.85 versus
9.39 ± 1.98, and 2.81 ± 0.92 versus 2.47 ± 0.83, resp.). Both
the BrainPower Advanced and the placebo groups produced
significant improvements (129%–150%) (𝑃 < 0.01, each) of
the subtests and combined total scores in the older adults,
with the BrainPower Advanced group producing better
improvements (1.50-, 1.35-, 1.43-, and 1.29-fold relative to the
baseline values of audio/visual memory, abstract thinking,
memory retrieval, and combined total function test scores)
than the placebo group (1.35-, 1.27-, 1.13-, and 1.27-fold, resp.)
(Tables 6(a) and 6(b)).
Ridit scoring test showed that the improvement in the
combined total scores of the memory function subtests was
significantly better after the BrainPower Advanced interven-
tion (mean = 0.56±0.287) than after the placebo intervention
(0.445 ± 0.276) (𝑃 < 0.05) (Table 6(c)).
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Table 6: (a) Subtest scores (mean ± s.d.) of memory function test before and after the interventions between BrainPower Advanced and
placebo groups. (b) Comparison of the combined totalmemory function test scores between BrainPowerAdvanced and placebo groups shows
no differences between the two groups before or after the interventions. However, BrainPower Advanced and placebo interventions both
improved the combined total scores significantly (𝑃 < 0.01 each). (c) Different impacts of BrainPower Advanced and placebo interventions
on the improvement of memory function tests. Ridit scoring test of the ranked data showed a better improvement after BrainPower Advanced
intervention than after placebo interventions (𝑃 < 0.05).
(a)
Memory function
subtest scores Before intervention After intervention
Improvement
relative
to baseline (= 1)
𝑡 𝑃
Audio/visual
memory
BrainPower 2.28 ± 1.06 3.43 ± 0.83 1.50 −8.247 <0.001
Placebo 2.51 ± 0.81 3.41 ± 1.00 1.36 −5.014 <0.001
𝑡 −1.232 0.074
𝑃 0.221 0.941
Abstracting ability
BrainPower 2.40 ± 1.08 3.45 ± 0.75 1.44 −6.602 <0.001
Placebo 2.73 ± 1.08 3.47 ± 0.92 1.27 −4.791 <0.001
𝑡 −1.474 0.081
𝑃 0.144 0.889
Memory retrieval
BrainPower 2.17 ± 1.15 2.81 ± 0.92 1.29 −3.526 0.001
Placebo 2.18 ± 1.14 2.47 ± 0.83 1.13 −1.820 0.075
𝑡 −.027 0.410
𝑃 0.979 0.060
(b)
Before intervention After intervention 𝑡 𝑃
BrainPower 6.85 ± 2.46 9.66 ± 1.85 8.478 <0.001
Placebo 7.37 ± 2.32 9.39 ± 1.98 6.988 <0.001
𝑡 −1.08 0.692
𝑃 0.283 0.491
(c)
Score change BrainPower intervention Placebo control Total
𝑁 % 𝑁 % 𝑁 %
−5 1 2.1 0 0 1 1
−3 0 0 1 2 1 1
−2 1 2.1 2 3.9 3 3.1
−1 1 2.1 5 9.8 6 6.1
0 2 4.3 2 3.9 4 4.1
+1 6 12.8 5 9.8 11 11.2
+2 7 14.9 17 33.3 24 24.5
+3 12 25.5 8 15.7 20 20.4
+4 9 19.1 5 9.8 14 14.3
+5 2 4.3 5 9.8 7 7.1
+6 4 8.5 0 0 4 4.1
+7 2 4.3 1 2 3 3.1
Total 47 100.0 51 100.0 98 100.0
4. Discussion
In this exploratory randomized, double-blind, placebo-
controlled study, we evaluated the effectiveness of a pro-
prietary dietary supplement, BrainPower Advanced, in
older adults with SMCs. The results show that BrainPower
Advanced intervention for 12 weeks was safe and effective in
improving the symptoms of SMC in older adults.
SMCs are defined as self-awareness of memory loss that
can be assessed by a simple “yes” or “no” questionnaire
but are often not detected by clinicians using objective
memory scales [2]. SMC is also a predictor of mild cognitive
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impairment (MCI) and of future cognitive decline [156, 157].
There are studies showing that peoplewith SMCare 3–6 times
more likely to develop MCI than people without SMC [158–
162].
Because SMCs are often reversible, improvement of SMC
would represent a good opportunity to intervene prodromal
MCI and cognitive decline. So far, no proven agents are
available for SMC. BrainPower Advanced is a dietary supple-
ment based on polyherbal extracts, nutrients, and vitamins.
Previous studies have shown that the active ingredients of
BrainPower Advanced could potentially improve cognitive
function in different age groups of healthy people in the
presence or absence of SMCs through various mechanisms
including anti-inflammation, improved cerebral blood flow
and perfusion, and improved glucose/energy metabolism
(Table 1).
In the present study, BrainPower Advanced treatment
reversed 13 of the 44 (29.5%) cases of severe SML and 15
of the 43 (34.9%) cases of severe SAD. In contrast, placebo
treatment reversed only 2 of the 39 (5.1%) cases of severe SML
(𝑃 > 0.05) and 5 of the 37 (13.5%) cases of severe SAD (𝑃 >
0.05). Furthermore, a greater proportion of the participants
showed various degrees of symptom improvement after
BrainPower Advanced intervention (72.3%, 34/47 for SML
and 76.6%, 36/47 for SAD) than after placebo treatment (49%,
25/51 for SML and 39.2%, 20/51 for SAD).
In contrast, a greater proportion of participants in the
placebo group reported worsened symptoms of SML (25.5%,
13/51) and SAD (31.4%, 16/51) or no change in SML (29.4%,
15/51) and SAD (29.4%, 15/51) compared to the BrainPower
Advanced group that reported worsened SML (2.1%, 1/47)
and SAD (2%, 2/47) or no change in SML (25.5%, 12/47) and
SAD (19.1%, 9/47) after the intervention.
The 29.5% reversion rate (13/44) of severe SML and 34.9%
reversion rate (15/43) of severe SADbyBrainPowerAdvanced
are comparable to the reported 15%–35% response rate of
MCI to AChEIs treatment and the 30% response rate of MCI
to NMDA receptor antagonist treatment [139]. Given that
there is no standard anti-SMC treatment yet, the current
results are very promising [140–142].
These results suggest that BrainPower Advanced is not
only effective in reducing a significant portion (about 30%) of
severe SMC and in reducing symptom severity in about 70%
of the subjects with SMCs, but also effective in reducing the
progression or worsening of SMCs. It is noted, however, that
25.5% of the people with severe SML showed no response to
BrainPower Advanced intervention.
In this study, no significant differences were found in
visual/auditory memory, abstract thinking, and memory
retrieval and in the combined total memory function test-
ing scores between the BrainPower Advanced and placebo
groups before or after the intervention. Both BrainPower
Advanced and placebo interventions resulted in significantly
improved memory function performance, albeit with the
BrainPower Advanced group showing better improvement
than the placebo group at a nonsignificant level.
Because both placebo and BrainPower Advanced inter-
vention enhanced the performance scores of the memory
function tests, this raised the possibility that factors other
than the intervention per se may be responsible for the
improvement. One such possibility is that the postinterven-
tion memory test score was unintendedly “enhanced” by
the preintervention test. Like any learning activity, practice
or repetition of the same learning task would improve
performance and produce better scores. This may not mean
that thememorywas “getting better” but simply reflecting the
remembered answers from the last test.There are suggestions
that the same memory tests should not be given within a
short period of time (3–6months) or that only the tests taken
the first time should be taken seriously as a true measure of
memory abilities.
It is the current view that SMC is a subjective experi-
ence that cannot be reliably measured by objective mem-
ory scales due to the subtle and heterogeneous nature of
SMC [2–5]. Nevertheless, more accurate diagnosis of SMC
and/or MCI could be corroborated by informants and by
using different questionnaires and memory scales before
and after an intervention such as the use of Mini-Mental
State Examination (MMSE), Six-Item Screener, Subjective
Memory Rating Scale (SMRS) and Deterioration Cognitive
Observee (DECO) [143], Memory Complaint Questionnaire
(MAC-Q), and Subjective Cognitive Decline Questionnaire
(SCD-Q) [144].The updatedWechslerMemory Scale (WMS)
also has a battery of subtests for evaluating multiple aspects
of learning and memory including immediate and delayed
memory for visual working memory and auditory memory
[145–148].
There are other limitations of this study. The sample size
is too small to detect potential performance differences in the
memory function tests. Despite the randomization process,
more participants in the BrainPower Advanced group had a
history of disease andmedication use than the placebo group.
Due to the multi-ingredient nature of BrainPower Advanced,
it was difficult to determine whether any single ingredient
(Ginkgo biloba, Camellia sinensis, vinpocetine, kola nut, hup
A, PS, L-tyrosine, L-pyroglutamic acid, acetyl-L-carnitine,
choline bitartrate, L-glutamine, L-phenylalanine, L-cysteine,
vitamin B6, or vitamin B12) was primarily responsible for
BrainPower Advanced overall effects or, more likely, whether
it was a synergistic combination of the ingredients working
together that produced the observed results. Because SMCs
are heterogeneous and potentially affected by a range of
genetic and epigenetic factors including lifestyle [149], daily
activity/exercise [150, 151], APOE genotype [163], affective
status [164–166], education achievements [11, 167], inflamma-
tion, and alcohol use, controlling these factors would allow
better understanding of BrainPower Advanced intervention
in further studies [168].
5. Conclusion
Twelve-week BrainPower Advanced intervention was effec-
tive and safe in reducing the progression of symptom severity
in older adults with severe SML and SAD. As no proven
agents are currently available in reversing or delaying the
progression of SMC in the increasing aging population,
further well-controlled, large-scale studies could validate if
long-term dietary supplementation of combined polyherbal
Evidence-Based Complementary and Alternative Medicine 11
ingredients, nutrients, and vitamins could be an alternative
prophylactic strategy for older adults with SMCs.
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